1. Scrip
  2. >>Focus On Asia

Birgitte Lane On Translational Skin Research At Singapore’s IMB: An Interview With PharmAsia News (Part 2 of 2)

 
• By Ed Lane

Singapore’s Biopolis, a campus-like setting of office and laboratory space set aside for biomedical research, hosts a skin biology cluster under the Institute of Medical Biology. Executive Director Professor Birgitte Lane spoke with PharmAsia News about efforts to attract industry to partner research with a translational focus.

SINGAPORE - Skin research has found a home at Singapore’s Institute of Medical Biology (IMB) – part of an acronym soup of research arms set up by the government under its Agency for Science, Technology and Research (A*STAR) to foster scientific development and talent.

IMB is one of 14 research institutes and consortia covering biomedical, physical, engineering and other sciences housed in two campus-like...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.